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Background: The precise etiology of knee osteoarthritis (KOA) pain remains highly controversial and there is no
known effective treatment. Due to the known and suggested effects of neuropeptide Y (NPY) on pain, we have
sought to investigate the relationship between the concentration of NPY in synovial fluid of knee, pain of KOA, and
structural severity of KOA.
Methods: One hundred KOA patients and twenty healthy participants (control group) were recruited. The pain and
the radiographic grade of KOA were assessed separately by Hideo Watanabe’s pain score and Tomihisa Koshino’s
scoring system. Synovial fluid of knee from all participants was collected with arthrocentesis. Radioimmunoassay
was used to examine the concentration of NPY in synovial fluid of knee.
Results: Concentrations of NPY in synovial fluid were significantly higher in KOA patients (124.7 ± 33.4 pg/mL)
compared with controls (64.8 ± 26.3 pg/mL) (p = 0.0297). According to Hideo Watanabe’s pain score, 100 KOA patients
were divided into 5 subgroups: no pain (n = 12), mild pain (n = 25), moderate pain (n = 37), strong pain (n = 19) and
severe pain (n = 7). Within the KOA group, significantly higher concentrations of NPY were found in each subgroup as
pain intensified (no pain 81.4 ± 11.7 pg/mL, mild pain 99.1 ± 23.2 pg/mL, moderate pain 119.9 ± 31.5 pg/mL, strong pain
171.2 ± 37.3 pg/mL and severe pain 197.3 ± 41.9 pg/mL). Meanwhile, according to Tomihisa Koshino’s scoring system,
100 KOA patients were divided into 3 subgroups: early stage (n = 30), middle stage (n = 53), advanced stage (n = 17).
Concentrations of NPY in middle and advanced stage groups of KOA patients were significant higher than early
stage group of KOA patients (early stage 96.4 ± 27.1 pg/mL, middle stage 153.3 ± 16.9 pg/mL, advanced stage
149.5 ± 36.7 pg/mL) (p = 0.0163, p = 0.0352). Concentrations of NPY in advanced stage group of KOA patients has no
significant difference compare with middle stage group of KOA patients (p = 0. 2175).
Conclusions: This study demonstrated the presence and variation of concentrations of NPY in the KOA joint fluid,
suggesting a role for NPY as a putative regulator of pain transmission and perception in KOA pain.
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Knee osteoarthritis (KOA) is a chronic degenerative joint
disorder that affects a large proportion of the popula-
tion, particularly in elderly people [1-6]. Epidemiological
studies have revealed that over 70% of people aged
65 years or older suffer from OA with the knee joint
being most commonly affected [7]. KOA patients’ major
clinical manifestation is chronic pain that typically* Correspondence: wldzzs@163.com; jw.lv@siat.ac.cn
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unless otherwise stated.worsens as a result of weight bearing, activity or
movement of the affected joint [8]. Synovial inflam-
mation raised intra-osseous pressure and mechanical
stresses on intra-articular and peri-articular ligaments
and tendons [9-11] are potential contributors to the
chronic pain encountered. However, the precise aeti-
ology of KOA pain remains highly controversial,
which limits the progress in developing effective
treatments for KOA pain [12].
Neuropeptide Y (NPY), a 36 amino acid peptide, is
one of the most widely distributed neuropeptides in the
nervous system [13,14]. It has diverse and complex
biological functions, such as capacity to influencetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cessing [15-17]. In addition, pathophysiological role of
NPY in infection and inflammation, as well as in auto-
immunity, has been suggested [18,19]. The up-regulation
of NPY in the dorsal root ganglia and spinal cord has
been shown in various models of inflammatory and
neuropathic pain [20-23] and around blood vessels in
the capsule of the joint [24-26]. NPY and its Y1 and Y2
receptors are located at key pain signaling centers
throughout the nervous systems [27-32]. Previous work
also suggested that joint pain results from the activation
of primary afferent nerve fibers by neuropeptides at the
joint [33-35]. Due to the known and suggested impor-
tant effects of NPY on pain, we hypothesized that NPY
may be involved in the pathogenesis of KOA pain.
Therefore, the aim of this study was to assess the rela-
tionship between concentrations of NPY in the synovial
fluid of knee, KOA pain, and structural severity of KOA.Methods
Ethics statement
This study is in accordance with the ethical principles of
the Declaration of Helsinki and was approved by the
Local Research Ethics Committee (Research Ethics Com-
mittee of People’s Hospital of Hangzhou, Nanjing Med-
ical University), and the trial number 023–01 from
Research Ethics Committee of People’s Hospital of
Hangzhou, Nanjing Medical University.
All participants provided informed, written consent.Table 1 Hideo Watanabe’s knee scoring system-related
pain score
Group Standard
No pain group Occasionally feeling fatigue or heaviness,
but no pain at any time
Mild pain group Pain at starting time of various activities or
occasionally during long-distance walking,
but no pain at rest
Moderate pain group Pain usually on walking, but pain gradually
subside after a brief rest
Strong pain group Persistent pain on walking, but pain gradually
mitigates after a rest, usually associate with
spontaneous pain
Severe pain group Persistent pain at any time, including walking
and restPatients
This one year study was conducted in People’s Hospital
of Hangzhou, Nanjing Medical University from January
2009 to January 2010.
One hundred KOA patients were recruited from the de-
partment of orthopedic surgery in People’s Hospital of
Hangzhou, fulfilling the American College of Rheumatology
clinical criteria for the diagnosis of KOA [36]. In case of
bilateral KOA, the more serious pain and/or edema and/
or deformed side (determined by the patient’s subjective
judgment) was assessed. Exclusion criteria included knee
joint trauma ever in their lives (periarticular fracture,
meniscectomy, etc.), other arthritis (gout, rheumatoid
arthritis, purulent arthritis, etc.), metabolic bone diseases
(osteoporosis, Paget’s disease, osteopetrosis, etc.), ma-
lignancy, bone tumor (multiple myeloma, etc.), primary or
secondary hyperparathyroidism, inflammatory arthropathy
and any knee surgery during the last 6 months. In
addition, patients were excluded if any anti-inflammatory
drugs (oral NSAID, etc.), odynolysis and/or cortico-
therapy were used within the past 4 weeks.
Twenty healthy participants between 35 and 65 years
of age without any diseases judged by the physician wererecruited from the People’s Hospital of Hangzhou as the
control groups.
KOA pain assessment
Pain was assessed by the physician based on the patient’s
medical history according to Hideo Watanabe’s knee sco-
ring system-related pain score [37]. Patients with KOA
were divided into 5 groups: no pain group, mild pain
group, moderate pain group, strong pain group and severe
pain group (Table 1).
KOA radiographic grade
Full-extension posterior-anterior radiographs (X-ray) of the
knees were obtained and assessed by the physician. The de-
gree of radiographic KOA in individual joints was graded
(0 to 5) by the study investigator using the Tomihisa
Koshino’s scoring system [38]. Grade 1 was considered
early stage, grade 2–3 was middle stage and grade 4–5
was advanced stage (Table 2).
Arthrocentesis & joint fluid sampling
All participants were in a supine position on a stretcher.
The same entry site was demarcated with a skin-marking
pen. The skin was prepared with povidone-iodine. A ste-
rile drape was placed around the site. Then the region was
anesthetized by placing a wheal of lidocaine, using a small
(25-gauge) needle. Intermittently the plunger was pulled
back during the injection of the anesthetic to exclude
intravascular placement.
An 18-gauge needle was used directly behind the patella
into the synovial cavity with the lateral approach. Upon in-
sertion into the articular cavity, 3 mL of 0.9% saline was
injected slowly into the joint and after 20s 3mL of turbid-
appearing fluid was aspirated and immediately centrifuged
(2000 rev/min, 10 min) at 4°C and stored at −70°C until
analyzed. Synovial fluid from healthy individuals were
collected, frozen, and stored in the same way as the KOA
patients.
Table 2 Tomihisa Koshino’s radiographic grading for
osteoarthritic knees in a weightbearing positiona
Stage Grade Standing x-ray
0 Normal
Early stage 1 Bone sclerosis or osteophyte formation
Middle stage 2 Narrowing of joint space (≤3 mm)
3 Obliteration of joint space or subluxationb
Advanced stage 4 Defect of tibial plateau (<5 mm)
5 Defect of tibial plateau (≥5 mm)
aAn anteroposterior and weight-bearing radiograph taken in a standing
position was used for grading.
b“Subluxation” indicates the condition in which the medial edge of the medial
tibial plateau shows a lateral shift by more than 5 mm against the medial edge of
articular surface of the medial femoral condyle without including osteophyte.
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Radio-immunoassay was performed to determine concen-
trations of NPY in KOA synovial fluid. Concentrations of
NPY in joint fluid was determined by commercially avail-
able radioimmunoassay kits (Iodine [125I] Neuropeptide
Radioimmunoassay kit, Institute of RIA, Chinese PLA
General Hospital, China) in accordance with the standard
protocols included in the kits. The sensitivity of the radio-
immunoassay kit was < 33 pg/mL.
Statistical analysis
All analyses were performed using SPSS version 13.0.
Data presented as mean ± SD. Bartlett’s method was per-
formed first to identify the homogeneity of variances.
Group t-test was used to compare the mean of concen-
trations of NPY in synovial fluid of KOA Group with
Healthy control group. Dunnett-t test was used to com-
pare the mean of concentrations of NPY in synovial fluid
of each subgroup of KOA Group with Healthy control
group. In addition, the Student-Newman-Keuls (SNK)
test was used to compare the mean of concentrations of
NPY in synovial fluid of each KOA subgroup. A linear
regression was used to assess the relationship between


















Figure 1 Comparison of pain and NPY concentrations of KOA patient
Intragroup KOA ★vs. No pain group, ■vs. Mild pain group, ●vs. Moderate paKOA patients. A p value less than 0.05 was considered
to be statistically significant.
Results
Participant demographics
In total, 100 KOA patients and 20 healthy controls partici-
pated in this study. The mean age of the KOA patients
was 56 ± 6.9 years and 48 ± 8.1 years for the healthy con-
trols, which was not significantly different (p = 0.347). The
gender distribution between the two groups was similar
with 39% of the KOA patients and 50% of healthy controls
being male (p = 0.3609).
KOA pain and NPY concentrations
As previously stated the KOA patients (n = 100) were di-
vided into 5 groups according to Hideo Watanabe’s pain
score: no pain group (n = 12), mild pain group (n = 25),
moderate pain group (n = 37), strong pain group (n = 19)
and severe pain group (n = 7) (Figures 1 and 2).
In all tested KOA groups, there was a positive correl-
ation between concentrations of NPY and the level of
pain. Concentrations of NPY were significantly higher in
KOA patients (124.7 ± 33.4 pg/mL) than in healthy par-
ticipants (64.8 ± 26.3 pg/mL) (p = 0.0297). Within KOA
subgroups, significantly higher concentrations of NPY
were found in each subgroup as pain increased (no
pain group 81.4 ± 11.7 pg/mL, mild pain group 99.1 ±
23.2 pg/mL, moderate pain group 119.9 ± 31.5 pg/mL,
strong pain group 171.2 ± 37.3 pg/mL and severe pain
group 197.3 ± 41.9 pg/mL).
KOA radiographic grade and NPY concentrations
As previously stated, 100 KOA patients were divided into 3
stage groups according to Tomihisa Koshino’s scoring sys-
tem: early (n = 30), middle (n = 53) and advanced (n = 17)
(Figure 3).
Concentrations of NPY were significantly higher in
the KOA patients (124.7 ± 33.4 pg/mL) compared to










s with healthy participants. (p < 0.05:▲ vs. Healthy control group;
in group, ※vs. Strong pain group).











Figure 2 The correlation between synovial fluid NPY concentration and pain of KOA patients. (1 = Healthy control group, 2 = No pain
group, 3 = Mild pain group, 4 = Moderate pain group, 5 = Strong pain group, 6 = Severe pain group).
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patients (153.3 ± 16.9 pg/mL, 149.5 ± 36.7 pg/mL) were
significantly higher compared to the early staged patients
(96.4 ± 27.1 pg/mL) (p = 0.0163, p = 0.0352). Concen-
trations of NPY in the advanced staged patients were not
significantly different compared to the middle staged pa-
tients (p = 0. 2175).
Discussion
Despite the widespread prevalence of KOA in the adult
population, very little is known about the source of
KOA pain, which may be initiated by chemical media-
tors in KOA joints [39]. Due to the role of NPY in pain
[20-23,27-32], we sought to study the effect of varying
concentrations of NPY in KOA joint fluid and its asso-
ciation with the pain, and structural severity of KOA. To
our knowledge, this is the first study specifically de-
signed to evaluate the relationship between concentra-
tions of NPY, KOA pain, and structural severity of KOA.
Our primary finding was that concentrations of NPY
were significantly higher in KOA patients compared to
healthy controls. The results of our study were in agree-
ment with the available clinical literature, which has also
found significantly higher concentrations of NPY in the
synovial fluid of patients with arthritis of the knee (crystal
















Figure 3 Comparison of radiographic grade and concentrations of NPY of
group; Intragroup KOA ★vs. Early stage group).arthritis, rheumatoid arthritis), compared to control pa-
tients with non-inflammatory joint disorders (lateral me-
niscus injury, medial meniscus injury, cruciate ligament
injury), admitted for arthroscopy [40,41].
With an increase in pain based on each KOA sub-
groups we found significantly higher concentrations of
NPY. This result was similar to literatures that found
that pain gradually developed from the initial mild pain
into a long period of severe pain during the pathological
process of KOA [9-12]. This indicates that levels of NPY
are related to the joint pain in patients with KOA.
Concentrations of NPY in synovial fluid of middle and
advanced KOA stages were significantly higher than
early KOA stage. But concentrations of NPY in synovial
fluid of advanced stage of KOA patients have no signifi-
cant difference to compare with middle stage of KOA
patients. These results contradict the notion that NPY
has significant relevance to joint pain in patients with
KOA, and significantly higher concentrations of NPY
may lead to a significant increase in pain. It suggests a
lack of agreement between X-rays evidence of KOA and
patients’ report of pain at that site base on the result of
our studies, which are the first study specifically designed
to evaluate the relationship between NPY and KOA pain.
Meanwhile, the orthopedic community has been plagued







KOA patients with healthy participants. (p < 0.05: ▲ vs. Healthy control
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pain and observed radiographic evidence of KOA. In a
2008 systematic review of population studies, Bedson and
Croft quantitatively described the problem for KOA: “In
those with radiographic KOA the proportion with pain
ranged from 15% to 81%” [47]. The discordance between
pain and radiographic KOA points to the need for further
investigation of this phenomenon. And, the different sub-
scales of classifications for grade of KOA may be one of
the causes. The obliteration of joint space, which is consid-
ered middle stage in this study, is quite advanced KOA and
according to the Kellgren-Lawrence scoring system would
represent end-stage KOA (grade 4). This may help explain
why no differences were found between middle and ad-
vanced KOA groups.
Studies have shown that during arthritis, pro-infla
mmatory mediators are released into the joint [48] which
sensitize the joint afferent neurons. This can cause pre-
vious innocuous physicochemical stimuli to activate these
neurons which will lead to the sensation of joint pain
[49,50]. One important family of agents known to be
involved in the peripheral sensitization of joint afferents
is the inflammatory neuropeptides, which include NPY
[30-32,51]. NPY (belonging to the pancreatic polypeptide
family) was first isolated from pig brain by Tatemoto [24].
NPY is produced together with noradrenaline in certain
sympathetic nerve fibers [25] and has a strong and long-
standing vasoconstrictive effect on both arterial and
venous vessels. In the rat, this neuropeptide was found
around blood vessels in the capsule of the joint, but not in
the disc or cartilaginous joint surfaces [26]. This potent
neuromodulator is stored in the terminal branches of Aδ
and C fibers where it’s release into the joint lowers the ac-
tivation threshold of nociceptive nerve endings, which is
likely to contribute to chronic, sensitized pain responses
[52]. Based on the current study, the presence and vari-
ation of NPY in KOA joint fluid strongly points to a role
as a regulator of pain transmission and perception in
KOA pain. Possible mechanisms by which NPY can mo-
dulate pain processing. NPY can lower membrane Ca2+
conductance in dorsal root ganglion neurons and inhibits
substance P released from the central terminals of the pri-
mary afferent fibers [14,53,54]. Furthermore, the observa-
tion that peripheral inflammation increases both NPY and
its Y1 and Y2 receptor synthesis in the spinal dorsal horn
reinforces the concept that spinal NPY participates in the
processing of nociception [12]. Noradrenergic neurons of
the locus coeruleus and A1 noradrenergic cell groups also
constitute a major system concerned with the modulation
of nociception [55] and NPY is co-localized with noradren-
aline in a sub-population of the neurons [25,56,57]. In the
locus coeruleus, NPY depresses the spontaneous firing rate
of these neurons and the hyperpolarizing effect of α2-ago-
nists through stimulation of its Y2 receptor subtype [58].Study limitations
This study is limited by a small sample size and the dif-
ferent sub-scales of classifications for pain and grade of
KOA. In addition, the underlying molecular and cellular
mechanisms of NPY in KOA pain remain poorly under-
stood. Hopefully, future studies will provide answers to
these questions.
Conclusions
This study demonstrated the concentrations of NPY bet-
ween KOA patients and healthy controls. These results
suggest a role for NPY as a putative regulator of pain
transmission and perception of KOA pain. In addition,
concentrations of NPY may reflect the pathological pro-
gressing and severity of KOA. The precise roles of NPY
in the pathogenesis of KOA pain require further investi-
gation. However, our results have contributed to a better
understanding of the molecular processes underlying
KOA pain and, in addition, foster the option of local
therapeutic intervention targeting NPY. The understan-
ding of the role of NPY in KOA pain is a prerequisite to
developing such novel therapeutic options for the treat-
ment of KOA pain and restoration of tissue function.
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